

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 60790

Manuscript Type: CASE REPORT

Dear Editor,

First, we would like to thank the reviewers for their insightful comments and suggestions.

Herewith we are enclosing answers to the reviewers' and editors' comments in this e-mail for manuscript No. 60790, we have tried our best to complete it as follows:

Comments from the reviewers and editors:

Reviewer #1:

1. The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016). However, there are some Omissions in the manuscript. For instance, A definite diagnosis of this patient is not given in the abstract.

Answers:

Thanks for your good suggestions. We have added the definite diagnosis in the abstract, please see the revised manuscript. (L50-52, P3)

2. There is no Timeline of “Information from this case report organized into a timeline (table or figure)”

Answers:

Thanks for your good suggestions. We have added the timeline, please see the revised manuscript. (L359-361, P15-16)

3. The patient information description is too simple, and the content is incomplete, such as no description of past history, personal history, genetic history, other Relevant history including past interventions and outcomes.

Answers:

Thanks for your valuable suggestions. We have completed the patient information in the section “CASE PRESENTATION”, please see the revised manuscript. (L126-145, P5-6)

4. It is just a simple list of the examination results, and the diagnostic basis and differential diagnosis content was not described in the article.

Answers:

Thanks for your good suggestions. We have revised and described the diagnostic basis and differential diagnosis in the section “CASE PRESENTATION” and “MULTIDISCIPLINE EXPERT CONSULTATION”, please see the revised manuscript. (L147-177, P6-7)

5. In the manuscript, the author listed some Chinese medicine with anticancer effect, such as *Scutellaria barbata* D. Don (Banzhilian), *Smilax glabra* Roxb. (Tufuling), *Panax notoginseng* (Burkill) F. H. Chen (Sanqi), *Scleromitrium diffusum* (Willd.) R. J. Wang (Baihuasheshicao), *Scutellaria barbata* D. Don (Banzhilian). However, As we all know, for the treatment of Glioblastoma, the drug must first pass through the blood-brain barrier. And can the main components in KLP pass through the blood-brain barrier? Please describe in detail.

Answers:

Thanks for your valuable comments. we have revised this and please see the revised manuscript. (L226-235, P9)

Recent studies have provided a preliminary understanding of the mechanism of traditional Chinese medicine in regulating the permeability of the blood-brain barrier. Some studies found that astilbin in *Smilax glabra* Roxb. (Tufuling) enter the brain tissue through the blood-brain barrier, at a low concentration, but with a long duration. Notoginseng saponins R1 and ginsenoside Rg1 in *Panax notoginseng* (Burkill) F. H. Chen (Sanqi) could penetrate the blood-brain barrier and enter the cerebrospinal fluid in rats. Few studies investigated the ability of *Scleromitrium diffusum* (Willd.) R. J. Wang and *Scutellaria barbata* D. Don to affect blood-brain barrier permeability, but we speculate that other components in KLP may also play a role in assisting the main components to enter the blood-brain barrier. We have tried our best to consult relevant literature, but unfortunately, we did not find the desired results. TCMs act on the human body through multiple channels and targets; however, the mechanism of KLP is still unclear.

6. Finally, English writing needs to be improved.

Answers:

Thank you very much for your careful review, we have revised this and please see the revised manuscript.

7. Some references are not written properly.

Answers:

Thank you very much for your careful review. We have replaced the references with the latest as far as possible. please see the revised manuscript.

Editor #:

1. I found the authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s);

Answers:

Thank you very much for your careful review. We have uploaded the funding agency copy of the approval documents, please see in the “60790- Funding Agency Copy of the Approval Documents”.

2. I found the authors did not provide the original figures. Please provide the original figure documents.

Answers:

Thank you very much for your careful review. We have provided the original figure documents, please see in the “60790-Figures.pptx”.

3. I found the “Case Presentation” did not meet our requirements. Please re-write the “Case Presentation” section, and add “FINAL DIAGNOSIS”, “TREATMENT”, and “OUTCOME AND FOLLOW-UP” section to the main text, according to the Guidelines and Requirements for Manuscript Revision.

Answers:

Thank you very much for your careful review. We have re-written the “Case Presentation” section, and added “FINAL DIAGNOSIS”, “TREATMENT”, and “OUTCOME AND FOLLOW-UP” section to the main text, according to the Guidelines and Requirements for Manuscript Revision., please see the revised manuscript. (L176-193, P7-8)